Tiantan Biological subsidiary completes hemophilia drug trials

Chengdu Rong Sheng Pharmaceutical, a subsidiary of Beijing Tiantan Biological Products Corp., completed Phase III clinical trials for its recombinant human coagulation factor VII injection. The trials on patients under 12 with hemophilia A showed routine preventative treatment significantly reduced bleeding frequency and improved joint health and quality of life.

The clinical trial involved R&D investment of 797.4m yuan. Further applications to the National Medical Products Administration are required, with approval timeline uncertain.